Salisbury NHS Foundation Trust Haematology Clinical Trials Portfolio

NHS Salisbury NHS Foundation Trust

Study Title	Treatment	Key Inclusion	Key Exclusion	Status
Acute Myeloid Leukaemia				
Optimise FLT3 (NIHR ID: 57535) Phase III Non-Commercial Newly Diagnosed with AML Optimise FLT3	**Randomisation** Control Arm 1 • DA-Midostaurin Experimental Arm 2 • DA-GO-Midostaurin Experimental Arm 3 • FLAG-IDA-GO-Midostaurin	Diagnosed with AML Age >= 16 Considered fit for intensive AML therapy Confirmed FLT3 ITD or TKD mutation	Receipt of any previous therapy for AML Other active malignancy requiring treatment Blast transformation of chronic myeloid leukaemia	OPEN Salisbury District Hospital Recruitment end date; 31/07/2029
PROPEL (NIHR ID: 56018) Phase III Non-Commercial AML in complete remission PROPEL PeRsOnalised PrEhabilitation in AML	**Randomisation** Control Arm 1 • Best Practice Usual Care Experimental Arm 2 • Personalised Prehabilitation Care Package	Diagnosis of AML in complete remission following induction chemotherapy Age>= 16 Prior to, or within the 1st course of treatment following remission Planned to receive at least one further full cycle of treatment (chemotherapy or HSCT) post randomisation Access to the internet & willing to use videoconferencing	Diagnosis of Acute Promyelocytic Leukaemia Undergoing single agent Azacitidine, single agent low dose Cytarabine, Menin inhibitors or FLT3 inhibitors treatments without HSCT planned	OPEN Salisbury District Hospital Recruitment end date; 31/08/2025 Recruitment to continue until request for extenstion granted
VICTOR (NIHR ID: 46867) Phase II Non-Commercial Newly Diagnosed with AML VICTOR	**Randomisation** Control Arm 1 • DAGO Experimental Arm 2 • VEN+LDAC	Diagnosis of CD33 positive AML Age>=55 Genotype $NPM1_{mut}$ $FLT3\ ITD_{neg}$ (FLT3- Tyrosine Kinase Domain mutation, TKD, is permitted) Considered fit for intensive chemotherapy	Previous chemotherapy for AML, or any antecedent haematological condition Other active malignancy requiring treatment	OPEN Salisbury District Hospital Recruitment end date; 01/06/2026
Chronic Lymphocytic Leukaemia				
P22-905 (PASS) (NIHR ID: 58169) Commercial Relapsed/refactory CLL patients abbvie	Survey to evaluate patients' receipt and use of the venetoclax patient card (PC) and their knowledge of the contents of the PC, including Tumour Lysis Syndrome (TLS) symptoms, patient actions to minimise TLS, and patient actions if TLS symptoms occur	Has initiated venetoclax for treatment of CLL in the past 8 weeks Age >= 18	Has received venetoclax as treatment for longer than 8 weeks	OPEN Salisbury District Hospital Recruitment end date; 30/04/2026

Study Title	Treatment	Key Inclusion	Key Exclusion	Status
STATIC (NIHR ID: 52879) Phase III Previously treated CLL Non-Commercial 	**Randomisation** Arm 1 • Intermittent treatment with a BTK inhibitor Arm 2 • Continuous treatment with a BTK inhibitor FLAIR and IcICLLe participants with progressive disease after completing 6 years of treatment, but prior to entry into STATIC, would not be eligible for randomisation, but can enter the Clinical Need Cohort. The Clinical Need Cohort will enable this group of participants to continue to receive ibrutinib continuous treatment	Age >= 18 Diagnosed with CLL or SLL Frontline Received 6 years of treatment on FLAIR or IcICLLe Previously Treated Currently receiving Ibrutinib or Acalabrutinib for at least 3 years Clinical Need Cohort Received 6 years of treatment on FLAIR or IcICLLe Has signs of progressive or returing CLL after completing 6 years of treatment	History or current evidence of Richter's transformation Frontline Treatment break for more than 28 days in last 12 months Disease progression Previously treated Treatment break for more than 28 days in last 12 months Disease progression Creatinine clearance <30ml/min Clinical Need Cohort Eligible for frontline randomisation Treatment other than Ibrutinib. Treatment break for more than 28 days in alst 12 months	OPEN Salisbury District Hospital Recruitment end date; 01/11/2028
BGB-16673-304 (CaDAnCe) (NIHR ID: 69446) Phase III Commercial Relapsed/refactory CLL or SLL 	**Randomisation** Arm A • BGB-16673 Arm B • Pirtobrutinib	Age >= 18 Previously treated for CLL or SLL with a cBTKi Have measurable disease (SLL only)	Known prolymphocytic leukemia or history of, or currently suspected Richter's transformation Autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 3 months Allogeneic stem cell transplant <=6 months before first dose of study drug	IN SET UP due to open 23/11/2025 Salisbury District Hospital Recruitment end date; 30/05/2027
Follicular Lymphoma				
OLYMPIA 5 (R1979-ONC-22102) (NIHR ID: 56593) Phase III Commercial Relapsed/Refractory FL/MZL REGENERON	**Randomisation** Arm A • Odronextamab (anti-CD20 x anti-CD3 bispecific antibody) plus Lenalidomide Arm B • Rituximab in combination with Lenalidomide	Local histologic confirmation of FL grade 1-3a or MZL (nodal, splenic, or extra nodal MZL) Must have refractory disease or relapsed after at least 1 prior line (with a duration of at least 2 cycles), should include an anti-CD20 Have measurable disease , nodal lesion of >1.5cm, extranodal >1cm	Participants with histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma A malignancy other than NHL, must be cancer free for at least 3 years Active infection	OPEN Salisbury District Hospital Recruitment end date; 31/01/2027 (Travel and expenses reimbursed by sponsor)